Sun Pharmaceuticals Industries Limited has announced that Sun Pharmaceutical Industries Ltd, along with its subsidiary ( Sun Pharma) has entered into a settlement agreement with Acorda Therapeutics, Inc. - See more at: http://ways2capital-review.blogspot.in/2015/10/sun-pharma-enters-into-agreement-with.html#sthash.Bqbs2zdI.dpuf
Sun Pharmaceutical Industries Ltd’s southward journey continues for yet another trading session. The scrip is currently trading 1.3% lower at Rs. 709.15 on BSE, which is a 16-month low level. - See more at: http://ways2capital-equitytips.blogspot.in/2015/11/sun-pharma-falls-13-pays-rs-500-cr.html#sthash.7RMIbaax.dpuf
Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec , Imatinib Mesylate tablets 100mg and 400mg Imatinib Mesylate tablets,
Sun Pharmaceutical Industries Ltd posted a net profit of Rs. 17136.90 million for the quarter ended March 31, 2016 where as the same was at Rs. 8892.40 - See more at: http://ways2capital-equitytips.blogspot.in/2016/05/sun-pharma-q4-net-profit-at-rs1713690-mn.html#sthash.V5x4pKck.dpuf
Shares of Sun Pharmaceutical Industries Ltd are currently trading 1.50% higher at Rs. 770.35 on BSE after it was reported by a financial daily that the company will raise Rs. 1,000 crore from the domestic bond market via its arm Sun Laboratories.